Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo is a research paper published in PLoS ONE (2023). On theSindex it has a DataRank of 0.330. It has been cited 8 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.330
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →DOD Peer Reviewed Cancer Research Program
Grant: CA181043
DOD Peer Reviewed Cancer Research Program
Grant: CA140515
Cancer Prevention and Research Institute of Texas
Grant: RP150578
Cancer Prevention and Research Institute of Texas
Grant: RP110532
NCI NIH HHS
Grant: P30 CA016672
NCI NIH HHS
Grant: R01 CA140515
National Institutes of Health
Grant: 3P30CA016672-41S4
Cancer Center Support (CORE) Grant
FWCI
0.92
Citation Percentile
0.7%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals